secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0000950170-24-009874
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharmaceuticals prices public offering of 4.325M shares at $19, expects ~$88.5M net proceeds
--------------------------------------------------------------------------------

- Priced 4,325,000 shares of common stock at $19.00 per share; underwriters' option for additional 648,750 shares exercised in full.
- Net proceeds expected to be approximately $88.5 million after underwriting discounts and estimated offering expenses.
- Offering expected to close on or about February 2, 2024; proceeds to fund clinical pipeline development and working capital.
- Jefferies acted as sole book-runner; H.C. Wainwright & Co. and Oppenheimer & Co. as lead managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/0000950170-24-009874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024009874/crbp-20240130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-009874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer